دورية أكاديمية
أعرض في EDS

Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles.

التفاصيل البيبلوغرافية
العنوان: Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles.
المؤلفون: Zhou AS; Molecular and Cellular Pharmacology Graduate Training Program, University of Wisconsin, Madison, Wisconsin, United States of America., Tucker JB; Cancer Biology Graduate Training Program, University of Wisconsin, Madison, Wisconsin, United States of America., Scribano CM; Molecular and Cellular Pharmacology Graduate Training Program, University of Wisconsin, Madison, Wisconsin, United States of America., Lynch AR; Cellular and Molecular Pathology Graduate Training Program, University of Wisconsin, Madison, Wisconsin, United States of America., Carlsen CL; Cellular and Molecular Biology Graduate Training Program, University of Wisconsin, Madison, Wisconsin, United States of America., Pop-Vicas ST; Department of Cell and Regenerative Biology, University of Wisconsin, Madison, Wisconsin, United States of America., Pattaswamy SM; Department of Cell and Regenerative Biology, University of Wisconsin, Madison, Wisconsin, United States of America., Burkard ME; Department of Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.; Department of Oncology/McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, Wisconsin, United States of America.; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, United States of America., Weaver BA; Department of Cell and Regenerative Biology, University of Wisconsin, Madison, Wisconsin, United States of America.; Department of Oncology/McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, Wisconsin, United States of America.; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, United States of America.
المصدر: PLoS biology [PLoS Biol] 2023 Oct 26; Vol. 21 (10), pp. e3002339. Date of Electronic Publication: 2023 Oct 26 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101183755 Publication Model: eCollection Cited Medium: Internet ISSN: 1545-7885 (Electronic) Linking ISSN: 15449173 NLM ISO Abbreviation: PLoS Biol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, [2003]-
مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , Poisons*/metabolism, Humans ; Microtubules/metabolism ; Spindle Apparatus ; Mitosis ; Kinetochores
مستخلص: Microtubule-targeted agents are commonly used for cancer treatment, though many patients do not benefit. Microtubule-targeted drugs were assumed to elicit anticancer activity via mitotic arrest because they cause cell death following mitotic arrest in cell culture. However, we recently demonstrated that intratumoral paclitaxel concentrations are insufficient to induce mitotic arrest and rather induce chromosomal instability (CIN) via multipolar mitotic spindles. Here, we show in metastatic breast cancer and relevant human cellular models that this mechanism is conserved among clinically useful microtubule poisons. While multipolar divisions typically produce inviable progeny, multipolar spindles can be focused into near-normal bipolar spindles at any stage of mitosis. Using a novel method to quantify the rate of CIN, we demonstrate that cell death positively correlates with net loss of DNA. Spindle focusing decreases CIN and causes resistance to diverse microtubule poisons, which can be counteracted by addition of a drug that increases CIN without affecting spindle polarity. These results demonstrate conserved mechanisms of action and resistance for diverse microtubule-targeted agents. Trial registration: clinicaltrials.gov, NCT03393741.
Competing Interests: M.E.B. declares the following: Medical advisory board of Strata Oncology; Research funding from Abbvie, Arcus, Apollomics, Elevation Oncology, Endeavor, Genetech, Puma, and Loxo Oncology, Seagen. All other authors declare that they have no conflict of interest.
(Copyright: © 2023 Zhou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5839-44. (PMID: 20167803)
Clin Cancer Res. 2012 Jan 1;18(1):51-63. (PMID: 22215906)
Br J Haematol. 2010 Aug;150(3):313-25. (PMID: 20560971)
Nature. 2014 Jun 5;510(7503):167-71. (PMID: 24739973)
Sci Transl Med. 2021 Sep 08;13(610):eabd4811. (PMID: 34516829)
J Clin Oncol. 1996 Feb;14(2):422-8. (PMID: 8636752)
Breast Cancer Res Treat. 2014 Jul;146(2):321-8. (PMID: 24699910)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Proc Natl Acad Sci U S A. 1989 Jun;86(12):4515-9. (PMID: 2660140)
Cancer Res. 2002 Apr 1;62(7):1935-8. (PMID: 11929805)
J Cell Biol. 1997 Dec 15;139(6):1373-82. (PMID: 9396744)
Anticancer Res. 2009 Nov;29(11):4373-80. (PMID: 20032381)
Biomolecules. 2019 Jan 26;9(2):. (PMID: 30691136)
J Clin Oncol. 1999 May;17(5):1413-24. (PMID: 10334526)
Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19108-13. (PMID: 19855003)
Nat Cell Biol. 2009 Jan;11(1):27-35. (PMID: 19060894)
Biochemistry. 2010 Feb 16;49(6):1331-7. (PMID: 20030375)
Mol Cancer Res. 2021 Jan;19(1):112-123. (PMID: 32948674)
Mol Biol Cell. 2005 Jul;16(7):3187-99. (PMID: 15843429)
Cell Cycle. 2019 Aug;18(15):1702-1713. (PMID: 31179849)
J Clin Oncol. 2007 Aug 10;25(23):3407-14. (PMID: 17606974)
Anticancer Agents Med Chem. 2010 Nov 1;10(9):697-712. (PMID: 21235439)
Cancer Cell. 2007 Jan;11(1):25-36. (PMID: 17189716)
EMBO J. 2020 Jan 15;39(2):e102924. (PMID: 31750958)
J Cell Biol. 1981 Nov;91(2 Pt 1):479-87. (PMID: 6118377)
EMBO J. 2010 Oct 20;29(20):3531-43. (PMID: 20852589)
Breast Cancer Res Treat. 2009 May;115(1):87-99. (PMID: 18483853)
J Clin Oncol. 2005 Aug 20;23(24):5542-51. (PMID: 16110015)
Clin Cancer Res. 2012 Sep 1;18(17):4764-74. (PMID: 22753585)
Ann Oncol. 2015 Oct;26(10):2180-92. (PMID: 26153498)
Cancer Chemother Pharmacol. 2012 Mar;69(3):733-41. (PMID: 22020315)
Invest New Drugs. 2012 Jun;30(3):1107-15. (PMID: 21494838)
Nature. 2022 Jul;607(7919):604-609. (PMID: 35831506)
J Biol Chem. 1996 Nov 22;271(47):29807-12. (PMID: 8939919)
Nat Rev Genet. 2020 Jan;21(1):44-62. (PMID: 31548659)
Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8699-704. (PMID: 15159543)
Mol Biol Cell. 2016 Jul 1;27(13):1981-9. (PMID: 27146113)
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5. (PMID: 6103535)
Nat Cell Biol. 2019 Jan;21(1):54-62. (PMID: 30602769)
Mol Biol Cell. 1997 Jun;8(6):973-85. (PMID: 9201709)
Nature. 1997 Apr 10;386(6625):623-7. (PMID: 9121588)
Invest New Drugs. 2013 Aug;31(4):1001-7. (PMID: 23329066)
Eur J Cancer. 2010 Aug;46(12):2206-15. (PMID: 20471824)
Biochemistry. 1980 Dec 23;19(26):6209-15. (PMID: 7470461)
Oncologist. 2009 Jun;14(6):559-70. (PMID: 19474163)
Am J Hum Genet. 2022 Dec 1;109(12):2126-2140. (PMID: 36459979)
Cell Rep. 2018 Jun 12;23(11):3366-3380. (PMID: 29898405)
Biochem Biophys Res Commun. 1976 Mar 22;69(2):319-24. (PMID: 1267789)
Cell Rep. 2017 Jun 20;19(12):2423-2431. (PMID: 28636931)
J Biol Chem. 1997 Jan 24;272(4):2534-41. (PMID: 8999970)
Curr Med Chem Anticancer Agents. 2002 Jan;2(1):1-17. (PMID: 12678749)
Cell. 2005 Jun 3;121(5):671-4. (PMID: 15935754)
Cancer Cell. 2009 Dec 8;16(6):475-86. (PMID: 19962666)
Mol Biol Cell. 2004 Aug;15(8):3771-81. (PMID: 15181147)
Cell Rep. 2015 Aug 4;12(5):809-20. (PMID: 26212324)
J Clin Oncol. 2007 Aug 10;25(23):3415-20. (PMID: 17606972)
Cancer Treat Rep. 1978 Aug;62(8):1219-22. (PMID: 688258)
J Clin Invest. 2012 Sep;122(9):3307-15. (PMID: 22863619)
Curr Biol. 2007 Feb 6;17(3):260-5. (PMID: 17276919)
Cancer Treat Rev. 2012 Oct;38(6):613-7. (PMID: 22155063)
ACS Med Chem Lett. 2010 Jan 19;1(1):30-4. (PMID: 24900171)
Cancer Cell. 2008 Aug 12;14(2):111-22. (PMID: 18656424)
Mol Biol Cell. 1995 Sep;6(9):1215-29. (PMID: 8534917)
Nat Commun. 2021 Sep 22;12(1):5576. (PMID: 34552071)
Nat Rev Clin Oncol. 2011 Feb 01;8(4):244-50. (PMID: 21283127)
Dev Cell. 2004 Nov;7(5):637-51. (PMID: 15525526)
Cell Rep. 2016 Jun 21;15(12):2679-91. (PMID: 27292643)
Ann Oncol. 1994 Nov;5(9):854-7. (PMID: 7848890)
Nature. 1968 Jun 22;218(5147):1176-7. (PMID: 5656643)
PLoS Genet. 2009 Oct;5(10):e1000705. (PMID: 19876375)
Cancer Discov. 2016 May;6(5):532-45. (PMID: 27001151)
Genes Dev. 2021 Aug 1;35(15-16):1079-1092. (PMID: 34266888)
Dis Model Mech. 2014 Jan;7(1):15-20. (PMID: 24396150)
Br J Cancer. 2012 Jul 10;107(2):280-6. (PMID: 22699824)
Cancer Res. 2007 Jan 1;67(1):160-6. (PMID: 17210695)
Dev Cell. 2017 Jun 19;41(6):638-651.e5. (PMID: 28633018)
Cancer Res. 1995 Jun 1;55(11):2325-33. (PMID: 7757983)
Pediatr Blood Cancer. 2010 Jul 15;55(1):3-4. (PMID: 20486161)
Apoptosis. 2021 Jun;26(5-6):248-252. (PMID: 33870441)
Cell. 2019 Jul 11;178(2):302-315.e23. (PMID: 31299200)
Cancer Res. 1991 Apr 15;51(8):2212-22. (PMID: 2009540)
Invest New Drugs. 2012 Jun;30(3):1088-95. (PMID: 21424701)
Br J Cancer. 2018 Jun;118(12):1586-1595. (PMID: 29736010)
Proc Natl Acad Sci U S A. 1976 Aug;73(8):2798-802. (PMID: 785472)
Biochemistry. 1995 Feb 21;34(7):2203-11. (PMID: 7857932)
Cell. 1998 Feb 6;92(3):401-13. (PMID: 9476899)
Mol Cancer Ther. 2014 Feb;13(2):275-84. (PMID: 24435445)
Cell Motil. 1981;1(4):445-54. (PMID: 6129064)
Sci Rep. 2016 Mar 09;6:22828. (PMID: 26956415)
Nature. 1979 Feb 22;277(5698):665-7. (PMID: 423966)
Nat Cell Biol. 2013 Sep;15(9):1079-1088. (PMID: 23955301)
Nature. 2001 Jan 18;409(6818):355-9. (PMID: 11201745)
FEBS Lett. 1979 Mar 15;99(2):333-6. (PMID: 428557)
Science. 2007 Aug 17;317(5840):916-24. (PMID: 17702937)
J Cell Biol. 2007 Oct 22;179(2):255-67. (PMID: 17938250)
Biochim Biophys Acta. 1981 Feb 18;673(1):86-92. (PMID: 7470507)
Mol Biol Cell. 2007 Aug;18(8):2970-9. (PMID: 17538014)
Sci Transl Med. 2014 Mar 26;6(229):229ra43. (PMID: 24670687)
Curr Biol. 2007 Feb 20;17(4):304-15. (PMID: 17291761)
Blood. 2010 Jun 24;115(25):5202-13. (PMID: 20382844)
Curr Biol. 2007 Feb 20;17(4):316-22. (PMID: 17291758)
J Clin Oncol. 2009 Jun 20;27(18):2954-61. (PMID: 19349550)
Nat Rev Cancer. 2004 Apr;4(4):253-65. (PMID: 15057285)
Endocr Relat Cancer. 2017 Sep;24(9):T107-T117. (PMID: 28808045)
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):E4134-41. (PMID: 24133140)
Semin Radiat Oncol. 2022 Jan;32(1):54-63. (PMID: 34861996)
معلومات مُعتمدة: T32 GM008688 United States GM NIGMS NIH HHS; T32 GM141013 United States GM NIGMS NIH HHS; P30 CA014520 United States CA NCI NIH HHS; R01 CA234904 United States CA NCI NIH HHS; T32 HG002760 United States HG NHGRI NIH HHS; T32 CA009135 United States CA NCI NIH HHS; F31 CA254247 United States CA NCI NIH HHS
سلسلة جزيئية: ClinicalTrials.gov NCT03393741
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Poisons)
تواريخ الأحداث: Date Created: 20231026 Date Completed: 20231030 Latest Revision: 20240426
رمز التحديث: 20240426
مُعرف محوري في PubMed: PMC10602348
DOI: 10.1371/journal.pbio.3002339
PMID: 37883329
قاعدة البيانات: MEDLINE
الوصف
تدمد:1545-7885
DOI:10.1371/journal.pbio.3002339